Lobe Sciences Ltd.
LOBEF · OTC
8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $0 | $0 |
| % Growth | -83.8% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $1 | -$0 | $0 |
| % Margin | 98.7% | 97.1% | – | – |
| R&D Expenses | $0 | $1 | $0 | $1 |
| G&A Expenses | $2 | $3 | $3 | $3 |
| SG&A Expenses | $2 | $3 | $4 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $2 | $4 | $4 | $6 |
| Operating Income | -$2 | -$3 | -$4 | -$6 |
| % Margin | -1,553.5% | -399.6% | – | – |
| Other Income/Exp. Net | -$2 | -$1 | -$8 | -$17 |
| Pre-Tax Income | -$4 | -$5 | -$12 | -$24 |
| Tax Expense | $0 | $0 | $0 | -$1 |
| Net Income | -$4 | -$5 | -$12 | -$10 |
| % Margin | -3,245.8% | -560% | – | – |
| EPS | -0.036 | -0.045 | -0.32 | -0.3 |
| % Growth | 19.7% | 85.9% | -6.7% | – |
| EPS Diluted | -0.036 | -0.045 | -0.32 | -0.3 |
| Weighted Avg Shares Out | 122 | 104 | 38 | 32 |
| Weighted Avg Shares Out Dil | 122 | 104 | 38 | 32 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$4 | -$4 | -$6 |
| % Margin | -3,021.9% | -525.9% | – | – |